US-based Abbott Laboratories has launched Simdax, a new treatment for acute decompensated heart failure, for the United Arab Emirates (UAE). The new drug was introduced at a recent event in the Ritz Carlton Hotel, Dubai.
At present, some 40 percent of people who experience an episode of acute decompensated heart failure die within a year. This high proportion has been condemned as excessive by cardiologists, who are hopeful that Simdax will make an impact on mortality rates among sufferers.
“We are confident that the availability of Simdax across the UAE will have a positive effect on survival rates at every stage after incidents of this most serious heart condition and provide us with another vital tool in the treatment of the disease”, said general manager of Abbott Laboratories Middle East, Ibrahim Aql.
The continuing high incidence of coronary heart disease in the UAE makes the introduction of effective new treatments especially important in the country, where the rate of deaths from cardiovascular illness has now outstripped the 25 per cent recorded in 2000. — (menareport.com)
© 2004 Mena Report (www.menareport.com)
